STOCK TITAN

Bausch Health Provides Company Update At 18th Annual Morgan Stanley Global Healthcare Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a presentation by CEO Joseph C. Papa and CFO Paul S. Herendeen at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. The presentation focuses on the company's business recovery post-COVID-19 and updates on its plan to spin off the eye health business. The presentation details are available on Bausch Health's Investor Relations page. Bausch Health aims to enhance global health through its pharmaceutical and medical products.

Positive
  • Update on business recovery post-COVID-19.
  • Progress report on the planned spin-off of its eye health business.
Negative
  • Uncertainties related to the COVID-19 pandemic may affect project development timelines and costs.
  • Risks surrounding the spin-off transaction, including expected benefits and costs.

LAVAL, Quebec, Sept. 16, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it has published a presentation that Joseph C. Papa, chairman and CEO, and Paul S. Herendeen, executive vice president and chief financial officer, are scheduled to present at the virtual 18th Annual Morgan Stanley Global Healthcare Conference today, Sept. 16, 2020, at 1:15 p.m. ET.

The presentation provides an update on Bausch Health's current business recovery in the wake of the COVID-19 pandemic, as well as an update and progress report regarding the Company's previously disclosed intention to spin off its eye health business.

The presentation is available on the Investor Relations page of the Bausch Health Companies Inc. web site at: http://ir.bauschhealth.com/events-and-presentations/2020. A live webcast and audio archive of the event will be also be available for 90 days.  

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase), risks and uncertainties relating to the Company's proposed plan to spin off its eye health business, including the expected benefits and costs of the spinoff transaction, the expected timing of completion of the spinoff transaction and its terms. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)


 

Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-provides-company-update-at-18th-annual-morgan-stanley-global-healthcare-conference-301132165.html

SOURCE Bausch Health Companies Inc.

FAQ

What is the focus of Bausch Health's presentation at the Morgan Stanley Global Healthcare Conference?

The presentation focuses on Bausch Health's business recovery after COVID-19 and the spin-off of its eye health business.

When is Bausch Health's presentation scheduled?

Bausch Health's presentation is scheduled for September 16, 2020, at 1:15 p.m. ET.

Where can I find Bausch Health's presentation details?

The presentation details are available on the Investor Relations page of Bausch Health's website.

What company updates did Bausch Health provide regarding COVID-19?

Bausch Health provided an update on its business recovery following the COVID-19 pandemic.

What risks are involved with Bausch Health's spin-off of its eye health business?

The spin-off involves uncertainties regarding the expected benefits, costs, and timing of completion.

Bausch Health Companies Inc.

NYSE:BHC

BHC Rankings

BHC Latest News

BHC Stock Data

3.17B
367.80M
11.08%
77.48%
3.27%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
QUEBEC